5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
PRIMES: Protein interaction machines in oncogenic EGF receptor signalling (PRIMES)
Date du début: 1 déc. 2011, Date de fin: 30 nov. 2016,
"PRIMES focuses on the role of protein interactions to assemble dynamic molecular machines that receive and process information to coordinate cellular responses. PRIMES investigates the following: (i) How do protein interactions contribute to the generation of biological specificity in signalling? (ii) How do pathogenetic perturbations affect protein interaction networks? (iii) How can we exploit ...
Voir le projet
14
Participants partenaires
TERMINÉ
Targeting Src-family tyrosine kinases in chronic autoimmune and inflammatory diseases (TARKINAID)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,
The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase family. Src-family kinases have recently emerged as major therapeutic targets in malignant diseases but their suitability as potential targets of inflammatory diseases has not yet recieved widespread acceptance. On the other hand, members of the applicant con ...
Voir le projet
11
Participants partenaires
TERMINÉ
New approaches for the targeted therapy of Non-Small Cell Lung Cancer (LUNGTARGET)
Date du début: 1 janv. 2011, Date de fin: 30 juin 2015,
Lung cancer is the most common cancer fatality in Europe (335000 deaths/yr). Non-small cell lung cancer (NSCLC) consists 85% of the cases, with 5 yr survival
Voir le projet
10
Participants partenaires
TERMINÉ
OPtimizing TArgets and Therapeutics In high risk and refractOry Multiple Myeloma (OPTATIO)
Date du début: 1 janv. 2012, Date de fin: 31 mars 2015,
Multiple Myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of the OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and therapeutic options. The MM pathogenesis involves not only genetic changes within the tumour cells but also the emergence of supportive conditions by the bone marrow microenv ...
Voir le projet
13
Participants partenaires
TERMINÉ
Exploiting Gram-negative cell division targets in the test tube to obtain anti-microbial compounds (DIVINOCELL)
Date du début: 1 mars 2009, Date de fin: 31 août 2013,
The DIVINOCELL project will identify novel Gram-negative targets by exploiting the components of the divisome, their activities and interactions. It will also design selective assays for screening and will obtain a new class of antimicrobials: compounds to block bacterial division. New medicines to attack Gram-negative pathogens will decrease the burden of infectious disease and have a highly ben ...
Voir le projet